Format

Send to

Choose Destination
Clin Ophthalmol. 2018 Aug 17;12:1473-1478. doi: 10.2147/OPTH.S174277. eCollection 2018.

Factors associated with fluctuations in repeated measurements of intraocular pressure using the Goldmann applanation tonometer in Japanese patients with primary open-angle glaucoma.

Author information

1
Department of Ophthalmology, Yaoeda Eye Clinic, Nagaoka, Niigata, Japan, surumeoyaji800@yahoo.co.jp.
2
Division of Ophthalmology and Visual Sciences, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan, surumeoyaji800@yahoo.co.jp.
3
Department of Ophthalmology, Kido Eye Clinic, Niigata, Niigata, Japan.
4
Department of Ophthalmology, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Abstract

Purpose:

The aim of this study was to determine whether fluctuations in intraocular pressure (IOP) occur as a result of the order of IOP measurements or successive IOP measurements in patients with glaucoma and, if so, identify the factors causing these fluctuations.

Patients and methods:

Four hundred twenty-eight eyes of 214 Japanese patients with primary open-angle glaucoma (POAG) were enrolled. Patients treated with beta-blockers or prostaglandin analogs alone were included. Additionally, in the IOP measurements by noncontact tonometer, the same cases of IOP of the right and left eyes prior to this study were included in this study. Four successive IOP measurements were carried out using a Goldmann applanation tonometer as follows: IOP was measured in the first eye (right or left) and then in the fellow eye and IOP was again measured in the first eye and then in the fellow eye. Repeated-measures analysis of variance was used to test the differences in IOP between successive measurements. Generalized linear mixed models were used to test differences in IOP measurements between the right and the left eyes on repeated applanation tonometry and according to the order of measurement. Conditional binomial logistic regression analysis was used to identify factors associated with fluctuating repeated applanation tonometry measurements. A P-value of <0.05 was considered statistically significant.

Results:

IOP values decreased significantly according to the number of measurements (13.8-13.0; P<0.001-0.036, respectively). There was no significant difference in IOP measurements between the right and left eyes. The first IOP measurement was significantly higher than the fourth measurement (P=0.038); however, there was no significant difference between other combinations. The use of a prostaglandin analog was the only significant contributor to fluctuating IOP measurements (P=0.002).

Conclusion:

IOP measured in the first eye, either right or left, was higher than that measured in the fellow eye in Japanese patients with POAG. The use of a prostaglandin analog may be associated with fluctuating IOP on repeated applanation tonometry.

KEYWORDS:

Goldmann applanation tonometer; glaucoma; intraocular pressure; measurement order; right and left eyes

Conflict of interest statement

Disclosure KY received grants from Alcon Japan Ltd. and nonfinancial support from Alcon Japan Ltd., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd; AF received grant from Alcon Japan Ltd. and nonfinancial support from Otsuka Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd.; MS received grant from Alcon Japan Ltd. and nonfinancial support from Alcon Japan Ltd. and Pfizer Japan Inc.; AM, none; and TF received grant from Abbott Medical Optics Inc., Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Company Ltd., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Alcon Japan Ltd., Retina Kitanihon Co., Ltd., Atsuzawa Proteze Co., Ltd., Shiga Medical Instruments Co., Ltd., and Union Medical Co., Ltd. and nonfinancial support from Abbott Medical Optics Inc., Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Company Ltd., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Alcon Japan Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Glaucos Japan Co., Ltd., and Abbvie Inc. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center